Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.33 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.31 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.31 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.31 |
| ▸ | AR | P10275 | 1/20 | 0.30 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.30 |
| ▸ | CD274 | Q9NZQ7 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3233813 | 0.83 | HSD17B1 (0.37) | AKR1C3CD274 | |
| SCHEMBL3243159 | 0.76 | SLC6A4 (0.40) | — | |
| SCHEMBL17840122 | 0.74 | FEN1 (0.42) | CHRM2CHRM1CHRM3ARAKR1C3 | |
| SCHEMBL76294 | 0.73 | ALDH1A1 (0.41) | CD274 | |
| SCHEMBL2132813 | 0.72 | FEN1 (0.41) | CHRM2CHRM1CHRM3ARAKR1C3 | |
| SCHEMBL2532136 | 0.71 | AR (0.40) | ARAKR1C3 | |
| SCHEMBL30665737 | 0.70 | PTPRC (0.48) | — | |
| SCHEMBL13439489 | 0.70 | PTPRC (0.48) | — | |
| SCHEMBL28453119 | 0.69 | FFAR4 (0.48) | FFAR4CD274 | |
| SCHEMBL2132817 | 0.67 | RPS6KA3 (0.40) | CHRM2CHRM1CHRM3AKR1C3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1225163-B1 | Process for producing isopulegol | TAKASAGO PERFUMERY CO LTD (JP) | 2010-07-28 | — | — | EP | disclosed |
| US-6774269-B2 | CYCLIZATION OF CITRONELLAL | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2004-08-10 | — | — | US | disclosed |
| US-20020133046-A1 | Process for producing isopulegol | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2002-09-19 | — | — | US | disclosed |
| EP-1225163-A2 | Process for producing isopulegol | Takasago International Corporation (JP) | 2002-07-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020133046-A1 | Process for producing isopulegol | ACSL3, ACSL1, ACSL6 | FFAR4 3704/4885CHRM2 1161/4885CHRM1 676/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.